article thumbnail

All in the Family Limited Partnership

Auto Dealer Valuation Insights

Many enterprising families have January 1, 2026, circled on their calendars. Because the individual estate tax exemption reverts to $6 million (give or take, depending on inflation) in 2026 from its current level of $12 million.

article thumbnail

Standard BioTools Completes Merger with SomaLogic, Creating a Diversified and Scaled Leader in Life Sciences Tools

Benzinga

Expediting scale to create an accelerated path to profitability with an estimated $80 million in annual cost synergies to be realized by 2026 [1]. Self-funding future growth initiatives through its formidable capital structure comprising over $500 million in cash and cash equivalents.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Shenandoah Telecommunications Company to Sell its Towers for $310 Million

Benzinga

"The proceeds from the sale of our Tower business will provide Shentel with additional growth capital to support the planned expansion of our Glo Fiber line of business to approximately 600,000 homes and business passings by the end of 2026.

article thumbnail

Clearway Energy, Inc. Signs Binding Agreement to Acquire 137 MW Wind Project

Benzinga

Based on current expected terms and conditions of the new non-recourse financing, the acquisition is expected to provide incremental annual levered asset CAFD on a five-year average basis of approximately $9 million beginning January 1, 2026. Clearway continues its successful track record of executing accretive, third-party acquisitions. .'s

article thumbnail

SomaLogic Issues Letter to Stockholders Reiterating Recommendation for Value Maximizing Merger with Standard BioTools

Benzinga

We expect this will deliver $300 million in combined revenue by 2026. Accelerates our path to profitability through enhanced operating leverage and an anticipated $80 million in run-rate cost synergies by 2026. The capital structure of the combined company is not risky.

article thumbnail

Standard BioTools and SomaLogic to Combine in All-Stock Merger Creating a Diversified Leader in Life Sciences Tools

Benzinga

The transaction is expected to generate $80 million in annual cost synergies by 2026. Produces a formidable capital structure with over $500 million in cash and cash equivalents expected at close to self-fund future growth initiatives. and BOULDER, Colo., 04, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc.